AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11368132
Drug: Adding myeloperoxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding myeloperoxidase (280 ng/ml) to neutrophil granulocyte suspensions
Trial: 9412638
Drug: Human pial
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human pial arteries contracted to KCl 30 mmol/L, norepinephrine 1 μmol/L, and vasopressin 0.1 μmol/L
Trial: 9412638
Drug: Human pial
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human pial arteries relaxed to acetylcholine 3 μmol/L
Trial: 8501160
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg MMI daily
Trial: 8501160
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg MMI daily
Trial: 2820202
Drug: Fibre supplement
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre supplement (5 g/day in Study I, 7 g/day in Study II)
Trial: 31005551
Drug: Polypharmacy (≥6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (≥6 drugs)
Trial: 28129275
Drug: Flexible Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible Daily Undulating Periodization (FDUP)
Trial: 28129275
Drug: Traditional Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Daily Undulating Periodization (DUP)
Trial: 25832541
Drug: Fresh red
RxNorm normalized name: Refresh Redness Relief
DrugBank: Polyvinyl alcohol (DB11060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fresh red onion meal (100 g providing 156.3 ± 3.4 μmol (47 mg) quercetin)
Trial: 25832541
Drug: Quercetin dihydrate
RxNorm normalized name: Quercetin dihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin dihydrate tablet (1800 ± 150 μmol (544 mg) of quercetin)
Trial: 7972346
Drug: Valerian extract
RxNorm normalized name: valerian extract
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian extract (Valdispert forte, 405 mg t.i.d.)
Trial: 1095248
Drug: Rifampicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin plus ethambutol daily for 2 months and then once a week (ER7ER1)
Trial: 1095248
Drug: Ethionamide plus
RxNorm normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethionamide plus pyrazinamide plus cycloserine daily for 6 months and then ethionamide plus pyrazinamide daily (EtZC)
Trial: 1095248
Drug: Rifampicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin plus ethambutol twice a week (ER2)
Trial: 1095248
Drug: Rifampicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin plus ethambutol daily (ER7)
Trial: 29045169
Drug: Topical palmitoylethanolamide
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical palmitoylethanolamide (PEA) (Defluxa)
Trial: 25483019
Drug: Greater daily
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater daily walking activity
Trial: 25483019
Drug: Total daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily walking activity
Trial: 10612768
Drug: Diabetes mellitus
RxNorm normalized name: diagnostic,monitoring agents for diabetes mellitus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes mellitus with a preoperative blood glucose level of 200 mg/dL or more
Trial: 9578541
Drug: Standard antiepileptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiepileptic drugs (optimal doses)
Trial: 8111800
Drug: Glyburide (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide (1.25 or 2.5 mg/day)
Trial: 8111800
Drug: Glipizide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (2.5 or 5 mg/day)
Trial: 8111800
Drug: Glyburide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide (mean dose 8.5 mg/day)
Trial: 8111800
Drug: Glipizide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (mean dose 15.4 mg/day)
Trial: 3903062
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (cisplatin, doxorubicin, cyclophosphamide: PACe)
Trial: 3903062
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (PACe)
Trial: 29343527
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for NF1-OPG
Trial: 29343527
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for sporadic OPG
Trial: 9665503
Drug: Indinavir 400
RxNorm normalized name: indinavir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 400 mg with delavirdine
Trial: 9665503
Drug: Indinavir 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 600 mg with delavirdine
Trial: 9665503
Drug: Indinavir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 800 mg alone
Trial: 7544368
Drug: FK 506
RxNorm normalized name: FK-960
DrugBank: FK-960 (DB06465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK 506 treatment
Trial: 912951
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B immune globulin (HBIG) administered at five to eight week intervals.
Trial: 19467804
Drug: 3D‐CRT planning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D‐CRT planning without mention of prostate or rectal contouring.
Trial: 19022811
Drug: High-dose immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose immunosuppressive therapy and autologous stem cell transplantation
Trial: 16855072
Drug: Sitagliptin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 200 mg bid
Trial: 12500203
Drug: VPA-985 25
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA-985 25 mg twice daily
Trial: 12500203
Drug: VPA-985 125
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA-985 125 mg twice daily
Trial: 12500203
Drug: VPA-985 250
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA-985 250 mg twice daily
Trial: 1297231
Drug: Glutathione (GSH,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione (GSH, 1200 mg, i.v.)
Trial: 29025005
Drug: Extended-release paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release paracetamol (ER-APAP) 2 x 665 mg
Trial: 27048210
Drug: Vortioxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (20 or 40 mg) with or without ethanol
Trial: 25293834
Drug: Haptotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haptotherapy treatment
Trial: 22516039
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing regimen (15 mg MTX once a week)
Trial: 22516039
Drug: Accelerated dosing
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated dosing regimen (25 mg MTX once a week)
Trial: 19853680
Drug: RUTI (5-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUTI (5-200 microg doses)
Trial: 16116012
Drug: Ketamine sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine sedation (0.5 mg . kg(‐1) . h(‐1) continuous infusion after IV administration of 0.01 mg/kg midazolam)
Trial: 16116012
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (volume-equivalent)
Trial: 10408158
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA) therapy for 2 weeks before LH-RH analogue injection
Trial: 10408158
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA) therapy for 4 weeks before LH-RH analogue injection
Trial: 10408158
Drug: LH-RH analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-RH analogue injection
Trial: 10408158
Drug: CMA administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CMA administration after LH-RH analogue application
Trial: 7673760
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SPECT score >= 4 and/or ST-depression in >= 3 leads
Trial: 28157491
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg dexamethasone (control)
Trial: 28157491
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg and 8 mg dexamethasone
Trial: 23332349
Drug: Docetaxel administered
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel administered concomitantly with capecitabine (DC)
Trial: 19471901
Drug: Conventional detoxification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional detoxification treatment (KE)
Trial: 15005830
Drug: Prandial subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prandial subcutaneous injections of rGLP-1 (76 nmol 30 min before meals, four times daily)
Trial: 15005830
Drug: Prandial subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prandial subcutaneous injections of rGLP-1
Trial: 15005830
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of rGLP-1 (12.7 nmol/h)
Trial: 29684501
Drug: Sputum rheology
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sputum rheology measures (G', G" and solids content)
Trial: 22832329
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol infusion (two concentrations)
Trial: 22832329
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol infusion (highest dose level)
Trial: 17934678
Drug: Routine asthma
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine asthma outcome measures (beta2-agonist prescription rate and number of oral steroid courses)
Trial: 15743537
Drug: Soy extract
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy extract capsules (2 capsules containing daidzin : genistin = 7.79 : 22.57 mg)
Trial: 15743537
Drug: Soy beverage
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy beverage (prepared from 15 g of soy flour containing daidzin : genistin = 9.27 : 10.51 mg)
Trial: 15743537
Drug: Soy extract
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy extract capsules
Trial: 9052446
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diet supplemented with 30 g per day of L-arginine for 3 days before surgery
Trial: 2893865
Drug: Intravenous penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous penicillin (6 million units/day for 7 days)
Trial: 31749238
Drug: Bexagliflozin 5
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexagliflozin 5 mg
Trial: 31749238
Drug: Bexagliflozin 10
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexagliflozin 10 mg
Trial: 31749238
Drug: Bexagliflozin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexagliflozin (all doses)
Trial: 31381171
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of alcohol (mean BrAC = 0.11%)
Trial: 31381171
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of alcohol (mean BrAC = 0.04%)
Trial: 28969667
Drug: CRP point-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP point-of-care test (POCT) to guide antibiotic prescribing
Trial: 14982685
Drug: bupropion (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupropion (300 mg) with behavioral counseling for 10 weeks
Trial: 21431408
Drug: CRS +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRS + HIPEC (cisplatin 120 mg and mitomycin C 30 mg in 6000 ml of normal saline at 43 ± 0.5°C for 60-90 min)
Trial: 18305083
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% 32 ml kg(‐1) (NS32)
Trial: 10606834
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg fosinopril (n=12 patients)
Trial: 10606834
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg enalapril (n=12 patients)
Trial: 10606834
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg fosinopril (n=16 patients)
Trial: 10606834
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg lisinopril (n=15 patients)
Trial: 8240458
Drug: Isradipine 10
RxNorm normalized name: isradipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 10 mg/day for 3 weeks
Trial: 25282563
Drug: Daily emollient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily emollient therapy applied at least once per day starting within 3 weeks of birth
Trial: 21073605
Drug: OAB-M-F (metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAB-M-F (metronidazole 500 mg bid for 5 days, followed by furazolidone 200 mg bid for 5 days)
Trial: 21073605
Drug: OAC-P (clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC-P (clarithromycin 500 mg bid for 10 days, placebo)
Trial: 21073605
Drug: OAB-C-F (clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAB-C-F (clarithromycin 500 mg bid for 5 days, followed by furazolidone 200 mg bid for 5 days)
Trial: 17713873
Drug: 2% sage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% sage extract (SE) in a hydrophilic ointment
Trial: 12153334
Drug: Nefazodone (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (starting at 50 mg/day, increasing to 200 mg/day, and up to 600 mg/day if tolerated)
Trial: 2521552
Drug: Inhaled pirenzepine
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled pirenzepine (70 micrograms)
Trial: 28505360
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cefazolin (500 mg h-1)
Trial: 28505360
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus of cefazolin (2 g every 4 h)
Trial: 25005464
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 gram orally 3 times daily for 3 months)
Trial: 25005464
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 gram orally 3 times daily for 3 months)
Trial: 23958263
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily for 6 months
Trial: 16983692
Drug: Particulate water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Particulate water (via aerosol spray)
Trial: 16357661
Drug: Developmental physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developmental physical therapy (PT) from birth until four months corrected age (CA), weekdays during the neonatal stay and on a needs- and problem-oriented basis thereafter.
Trial: 10500946
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg kg‐1 (Group M)
Trial: 6859607
Drug: Thiopental 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 3 mg/kg, iv, followed by inhalation of 100% oxygen and a continuous intravenous infusion of thiopental 0.2‐0.3 mg X kg‐1 X min‐1
Trial: 6859607
Drug: Thiopental 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 3 mg/kg followed by inhalation of halothane (1.5% end‐tidal concentration) in oxygen
Trial: 6859607
Drug: Thiopental 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 3 mg/kg followed by inhalation of 70% nitrous oxide in oxygen
Trial: 31409425
Drug: Postoperative guideline
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative guideline rehabilitation plus Classic follow-up treatment
Trial: 27142743
Drug: Theaflavins (TF)
RxNorm normalized name: theaflavin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theaflavins (TF) 10mg/kg single oral dose
Trial: 22315746
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) nasal spray 110 microg/day
Trial: 22315746
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) nasal spray 200 microg/day
Trial: 17928806
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg elemental calcium daily for 30 days (n=24)
Trial: 16905024
Drug: Mass antibiotic
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass antibiotic treatment (azithromycin)
Trial: 10233493
Drug: VIP/P-1 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP/P-1 (25 micrograms VIP combined with 1.0 mg PM)
Trial: 10233493
Drug: VIP/P-2 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP/P-2 (25 micrograms VIP combined with 2.0 mg PM)
Trial: 353721
Drug: Nomifensine, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine, 4 capsules daily for 4 weeks
Trial: 353721
Drug: Nortriptyline, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline, 4 capsules daily for 4 weeks
Trial: 31278694
Drug: Morphine ARER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine ARER 100 mg under fed conditions
Trial: 31278694
Drug: Morphine ARER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine ARER 100 mg under fasted conditions
Trial: 28557548
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) at 20-60 mg/day
Trial: 28557548
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT)
Trial: 26559364
Drug: Wet-cupping (hijama)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet-cupping (hijama) in addition to conventional hypertension treatment
Trial: 26559364
Drug: Conventional hypertension
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional hypertension treatment only
Trial: 16927385
Drug: Short and
RxNorm normalized name: ALLERGENIC EXTRACT,RAGWEED,SHORT AND TALL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short and long term family therapy
Trial: 9499549
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg medrogeston for six cycles
Trial: 9499549
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dydrogesteron for six cycles
Trial: 2677376
Drug: Trimazosin (50‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimazosin (50‐200 mg twice daily)
Trial: 2677376
Drug: Propranolol (40‐160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40‐160 mg twice daily)
Trial: 1108350
Drug: Trimethoprim-sulphamethoxazole, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulphamethoxazole, 2 tablets twice a day
Trial: 1108350
Drug: Ampicillin, 500
RxNorm normalized name: Ampicillin, 500 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin, 500 mg four times a day
Trial: 26094857
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor blockade by exendin-9-39
Trial: 19632976
Drug: Quit Smoking
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quit Smoking Network (QSN) treatment program
Trial: 19632976
Drug: Non-assigned treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-assigned treatments (various types)